Tracy Batchelor, MD, MPH
Correa DD et al. Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol 2007;18(7):1145-51. Abstract
Doolittle ND et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 2013;81(1):84-92. Abstract
Juergens A et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010;67(2):182-9. Abstract
Lai R et al. Treatment-induced leukoencephalopathy in primary CNS lymphoma: A clinical and autopsy study. Neurology 2004;62(3):451-6. Abstract
Morris PG et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome. J Clin Oncol 2013;31(31):3971-9. Abstract
Nguyen PL et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23(7):1507-13. Abstract
Omuro AMP et al. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study. Proc ASCO 2013;Abstract 2032.
Rubenstein JL et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013;31(25):3061-8. Abstract
Thiel E et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11(11):1036-47. Abstract
Nicholas Butowski, MD
Armstrong TS et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Proc ASCO 2013;Abstract 2003.
Chinot O et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Mature progression-free survival and preliminary overall survival results in AVAglio. SNO 2012;Abstract OT-03.
Gilbert MR et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). Proc ASCO 2013;Abstract 1.
Henriksson R et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Proc ASCO 2013;Abstract 2005.
Johnson DR et al. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis. Cancer 2013;119(19):3489-95. Abstract
Saran F et al. The addition of bevacizumab (BEV) to temozolomide (TMZ) and radiation therapy (RT) in newly diagnosed glioblastoma (GBM) improves progression-free survival (PFS) without adding to RT toxicity. ASTRO 2013;Abstract 37.
Sulman EP et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). Proc ASCO 2013;Abstract LBA2010.
Wefel JS et al. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825. Proc ASCO 2013;Abstract 2004.
Wick W et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Proc ASCO 2013;Abstract 2002.
Howard Colman, MD, PhD
Kesari S et al. Phase III trial of tumor-treating fields (TTFields) together with temozolomide compared with temozolomide (TMZ) alone in patients with newly diagnosed glioblastoma multiforme (NCT00916409). Proc ASCO 2012;Abstract TPS2106.
Kirson ED et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 2007;104(24):10152-7. Abstract
Kirson ED et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004;64(9):3288-95. Abstract
Raizer JJ et al. BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. Proc ASCO 2013;Abstract 2019.
Reardon D et al. ReACT: A phase II study of rindopepimut vaccine (CDX-110) plus bevacizumab in relapsed glioblastoma. SNO 2013;Abstract IT-018.
Reardon DA et al. REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB). Proc ASCO 2012;Abstract TPS2103.
Stupp R et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48(14):2192-202. Abstract
Westphal M et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(9):823-33. Abstract
Wong ET et al. Analysis of the response profile to NovoTTF-100A treatment in patients with recurrent GBM: Time to effect, response duration and transient progressions in the EF-11 phase III trial. SNO 2012;Abstract NO-47.
Minesh Mehta, MD
Furuse M et al. Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET. Jpn J Clin Oncol 2013;43(3):337-41. Abstract
Furuse M et al. Bevacizumab for progressive radiation necrosis: Preliminary results and ongoing clinical trial. SNO 2012;Abstract OT-01.
Perry JR et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). Proc ASCO 2012;Abstract TPS2104.
Stupp R et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. Proc ASCO 2013;Abstract LBA2009.
Tabatabai G, Weller M. Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE). Proc ASCO 2012;Abstract TPS2105.
Zhou LF et al. The Stupp regimen preceded by early post-surgery temozolomide versus the Stupp regimen alone in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM). Proc ASCO 2013;Abstract 2022.
Michael A Vogelbaum, MD, PhD
Baumert BG et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). Proc ASCO 2013;Abstract 2007.
Fisher BJ et al. A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424. Proc ASCO 2013;Abstract 2008.
Lacroix M et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190-8. Abstract
McGirt MJ et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 2009;65(3):463-9. Abstract
Stummer W et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: A supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg 2011;114(3):613-23. Abstract